scholarly journals Apolipoprotein E4‐driven effects on inflammatory and neurotrophic factors in peripheral extracellular vesicles from cognitively impaired not demented participants converted to Alzheimer’s disease

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Mohamed Raâfet Ben Kheder ◽  
Mohamed Haddad ◽  
Danielle Laurin ◽  
Charles Ramassamy
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Extracellular Vesicles ◽  
Neurotrophic Factors ◽  
Cognitively Impaired ◽  
Apolipoprotein E4

Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease

2019 ◽  
Vol 184 ◽  
pp. 111175 ◽  
Author(s):  
Tao-Ran Li ◽  
Xiao-Ni Wang ◽  
Can Sheng ◽  
Yu-Xia Li ◽  
Frederic Zhen-Tao Li ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Detection ◽  
Extracellular Vesicles

A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease

1993 ◽  
Vol 163 (2) ◽  
pp. 166-168 ◽  
Author(s):  
Akira Ueki ◽  
Mikihiko Kawano ◽  
Yoshio Namba ◽  
Masanobu Kawakami ◽  
Kazuhiko Ikeda
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
High Frequency ◽  
Late Onset ◽  
Japanese Patients ◽  
Apolipoprotein E4

scholarly journals Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer’s Disease and Other Dementias

2020 ◽  
pp. 1-14
Author(s):  
Yi-Wen Bao ◽  
Anson C.M. Chau ◽  
Patrick Ka-Chun Chiu ◽  
Yat Fung Shea ◽  
Joseph S.K. Kwan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Amyloid Β ◽  
Standardized Uptake Value ◽  
Subjective Cognitive Decline ◽  
Cognitively Impaired ◽  
Memory Clinic ◽  
Pet Ct

Background: With the more widespread use of 18F-radioligand-based amyloid-β (Aβ) PET-CT imaging, we evaluated Aβ binding and the utility of neocortical 18F-Flutemetamol standardized uptake value ratio (SUVR) as a biomarker. Objective: 18F-Flutemetamol SUVR was used to differentiate 1) mild cognitive impairment (MCI) from Alzheimer’s disease (AD), and 2) MCI from other non-AD dementias (OD). Methods: 109 patients consecutively recruited from a University memory clinic underwent clinical evaluation, neuropsychological test, MRI and 18F-Flutemetamol PET-CT. The diagnosis was made by consensus of a panel consisting of 1 neuroradiologist and 2 geriatricians. The final cohort included 13 subjective cognitive decline (SCD), 22 AD, 39 MCI, and 35 OD. Quantitative analysis of 16 region-of-interests made by Cortex ID software (GE Healthcare). Results: The global mean 18F-Flutemetamol SUVR in SCD, MCI, AD, and OD were 0.50 (SD-0.08), 0.53 (SD-0.16), 0.76 (SD-0.10), and 0.56 (SD-0.16), respectively, with SUVR in SCD and MCI and OD being significantly lower than AD. Aβ binding in SCD, MCI, and OD was heterogeneous, being 23%, 38.5%, and 42.9% respectively, as compared to 100% amyloid positivity in AD. Using global SUVR, ROC analysis showed AUC of 0.868 and 0.588 in differentiating MCI from AD and MCI from OD respectively. Conclusion: 18F-Flutemetamol SUVR differentiated MCI from AD with high efficacy (high negative predictive value), but much lower efficacy from OD. The major benefit of the test was to differentiate cognitively impaired patients (either SCD, MCI, or OD) without AD-related-amyloid-pathology from AD in the clinical setting, which was under-emphasized in the current guidelines proposed by Amyloid Imaging Task Force.

Apolipoprotein E4 and Cholinergic Dysfunction in Alzheimer’s Disease

1994 ◽  
pp. 72-76 ◽  
Author(s):  
Judes Poirier ◽  
Isabelle Aubert ◽  
Philippe Bertrand ◽  
Rémi Quirion ◽  
Serge Gauthier ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Apolipoprotein E4 ◽  
Cholinergic Dysfunction

Apolipoprotein E4 and Cholinergic Activity in Alzheimer’s Disease

1997 ◽  
pp. 55-60
Author(s):  
Judes Poirier ◽  
Isabelle Aubert ◽  
Rémi Quirion ◽  
Serge Gauthier ◽  
Martin Farlow ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinergic Activity ◽  
Apolipoprotein E4

A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild–Moderate Alzheimer’s Disease

CNS Drugs ◽  
2014 ◽  
Vol 28 (12) ◽  
pp. 1185-1189 ◽  
Author(s):  
Michael H. Rosenbloom ◽  
Terry R. Barclay ◽  
Maria Pyle ◽  
Brian L. Owens ◽  
Amanda B. Cagan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Single Dose ◽  
Pilot Trial ◽  
Apolipoprotein E4 ◽  
Acting Insulin
Sign in / Sign up

Export Citation Format

Share Document